Drug intelligence / Profile preview

Cry5B

Development stage
Preclinical
Lead developer
UMass Chan Medical School
Modality
Recombinant Proteins and Enzymes
Administration
Oral
01

Overview

Cry5B is a pore-forming crystal protein produced by the soil bacterium *Bacillus thuringiensis*. It is being developed as a novel, safe, and highly effective anthelmintic therapeutic for the treatment of soil-transmitted helminth (STH) infections, including hookworms (*Ancylostoma ceylanicum*, *Necator americanus*), whipworms (*Trichuris*), and large roundworms (*Ascaris*). Cry5B acts by binding selectively to invertebrate-specific glycosphingolipids and cadherin CDH-8 receptors on the apical membrane of the nematode intestine. This binding triggers oligomerization and insertion of the protein into the membrane, forming lytic pores that disrupt membrane integrity, leading to intestinal damage and death of the parasite. Because vertebrates lack the specific glycosphingolipid receptors required for Cry5B binding, the protein is non-toxic to humans and other mammals, offering a highly favorable safety profile.

Other names
Bacillus thuringiensis Cry5B ProteinCry5B proteinCry-5B proteinCry 5B proteinCry5Ba1Cry-5Ba1Cry 5Ba1recombinant Cry5B

Beyond the preview

Go deeper on Cry5B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cry5B.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call